Pimecrolimus Identifies a Common Genomic Anti-inflammatory Profile, is Clinically Highly Effective in Psoriasis and is Well Tolerated
- 1 October 2002
- journal article
- clinical trial
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 119 (4) , 876-887
- https://doi.org/10.1046/j.1523-1747.2002.00694.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Consensus Conference on cyclosporin A for psoriasis February 1992British Journal of Dermatology, 2008
- Treatment of Severe Psoriasis With Anti-CD25 Monoclonal AntibodiesArchives of Dermatology, 2000
- Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibodyClinical and Experimental Dermatology, 2000
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Ascomycins: promising agents for the treatment of inflammatory skin diseasesExpert Opinion on Investigational Drugs, 2000
- Anti-CD4 monoclonal antibody therapy in severe psoriasisJournal of Autoimmunity, 1992
- The immunology of psoriasisBritish Journal of Dermatology, 1992
- CD4 antibody treatment of severe psoriasisThe Lancet, 1991
- Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasisThe Lancet, 1991
- Remission of psoriatic lesions with muromonab-CD3 (Orthoclone OKT3) treatmentJournal of the American Academy of Dermatology, 1989